Abstract
The experimental drug AG-120, which inhibits mutant IDH1, showed promising results in a phase I trial in patients with relapsed or refractory acute myeloid leukemia.
©2015 American Association for Cancer Research.
MeSH terms
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Clinical Trials, Phase I as Topic
-
Enzyme Inhibitors / pharmacology
-
Enzyme Inhibitors / therapeutic use*
-
Humans
-
Isocitrate Dehydrogenase / antagonists & inhibitors*
-
Isocitrate Dehydrogenase / genetics
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myeloid, Acute / enzymology
-
Leukemia, Myeloid, Acute / genetics
-
Mutation
Substances
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Isocitrate Dehydrogenase
-
IDH1 protein, human